isonics em pre market a estoirar 17%
Acabei de reentrar a 5.80
risco elevado mas pago para ver !!!
Cumprimentos
Cumprimentos
- Mensagens: 197
- Registado: 10/11/2002 23:04
- Localização: Alentejo
Bullet Escreveu:ja agora fui eu q coloquei o post
Comentarios starter, quico sff
O meu comentário é que esta empresa aparece com novidades sempre que a cotação começa a descer, e de repente la dispara ela uns 15%. Ou seja esta muito duro para o trading (mais ou menos)consistente...
A verdade é que as descidas tem sido feitas com volumes fracos, o que é um bom sinal.
Vou acompanhar com interesse a sessão de hoje! Há uns rumores interessantes no mercado que a variação de preço deverá ou não reflectir.
Cumps
Starter
-
- Mensagens: 1047
- Registado: 15/11/2002 20:42
- Localização: Gloria-Aveiro
isonics em pre market a estoirar 17%
isonics no pre market ja sobe 17% OMG
Isonics Begins Supplying Rare Cancer-Fighting Isotope to National Institutes of Health
Wednesday January 5, 6:00 am ET
GOLDEN, Colo.--(BUSINESS WIRE)--Jan. 5, 2005--Isonics Corporation (Nasdaq:ISON - News), committed to the development of next-generation technology for the homeland security and semiconductor markets and provider of isotopes for the imaging and treatment of cancer, has announced the first delivery of Actinium-225, a rare but promising cancer-fighting radio-isotope to the National Cancer Institute, a part of the National Institutes of Health (NIH), the federal government's leading medical research organization. Scientists at the NIH have informed Isonics that the initial evaluation of the Isonics-supplied Actinium was satisfactory. The announcement was made by James E. Alexander, Chairman and CEO of Isonics.
ADVERTISEMENT
The isotope Bismuth-213, the radioactive decay product of Actinium-225, has shown promising results in research into new treatments for two deadly cancers, lymphoma and leukemia. Despite early evidence suggesting powerful efficacy of Bismuth-213 treatment for a range of cancers and other serious disease, medical research has in the past been slowed by short supply and high costs of available Actinium-225.
Through its Life Sciences division, Isonics has recently entered into an agreement with the Russian-based Institute for Physics and Power Engineering (IPPE) to significantly boost worldwide supplies of the scarce isotope. Under the agreement, Isonics will provide financial support to increase IPPE's production capacity.
Isonics has received exclusive marketing and sales rights for all of the Actinium-225 produced by IPPE. Assuming that IPPE reaches target production levels over the next year, Isonics expects that this will nearly double the existing global supply of Actinium-225. Currently, research includes clinical trials for therapies for leukemia and lymphoma. Numerous pre-clinical results have been published demonstrating the potential application of Bismuth-213 as a therapeutic for metastatic disease, bone marrow transplant, as well as treatments of fungal and bacterial infection.
Independent medical researchers welcomed the projected Actinium supply increases. "Clinical results to date have looked very promising, but lack of availability of the isotope Actinium-225 and the present high cost for that which is available has greatly limited the research," said Dr. Barbara Y. Croft, of the National Cancer Institute. "I am greatly encouraged that Isonics is working with IPPE to expand availability of Actinium-225, which will enable a greater number of promising research projects to proceed."
In clinical trials, Bismuth-213 has been used in a mode of cancer treatment called alpha immunotherapy, which researchers believe could lead to development of a so-called "magic bullet" for cancer treatment. The therapy involves the combination of alpha particle-emitting radio-nuclides -- in this case, Bismuth-213 -- with monoclonal antibodies or peptides that occur naturally in the human body. In the NIH research, the Bismuth-213 is combined with one such monoclonal antibody, and then injected into a cancer patient. The antibodies recognize and specifically bond to malignant cancer cells. When the Bismuth-213 decays, it imparts alpha particles into the cancerous cells with low risk of damaging the surrounding healthy cells.
BEST PICK 2005...double digit ate ao final do mes
Isonics Begins Supplying Rare Cancer-Fighting Isotope to National Institutes of Health
Wednesday January 5, 6:00 am ET
GOLDEN, Colo.--(BUSINESS WIRE)--Jan. 5, 2005--Isonics Corporation (Nasdaq:ISON - News), committed to the development of next-generation technology for the homeland security and semiconductor markets and provider of isotopes for the imaging and treatment of cancer, has announced the first delivery of Actinium-225, a rare but promising cancer-fighting radio-isotope to the National Cancer Institute, a part of the National Institutes of Health (NIH), the federal government's leading medical research organization. Scientists at the NIH have informed Isonics that the initial evaluation of the Isonics-supplied Actinium was satisfactory. The announcement was made by James E. Alexander, Chairman and CEO of Isonics.
ADVERTISEMENT
The isotope Bismuth-213, the radioactive decay product of Actinium-225, has shown promising results in research into new treatments for two deadly cancers, lymphoma and leukemia. Despite early evidence suggesting powerful efficacy of Bismuth-213 treatment for a range of cancers and other serious disease, medical research has in the past been slowed by short supply and high costs of available Actinium-225.
Through its Life Sciences division, Isonics has recently entered into an agreement with the Russian-based Institute for Physics and Power Engineering (IPPE) to significantly boost worldwide supplies of the scarce isotope. Under the agreement, Isonics will provide financial support to increase IPPE's production capacity.
Isonics has received exclusive marketing and sales rights for all of the Actinium-225 produced by IPPE. Assuming that IPPE reaches target production levels over the next year, Isonics expects that this will nearly double the existing global supply of Actinium-225. Currently, research includes clinical trials for therapies for leukemia and lymphoma. Numerous pre-clinical results have been published demonstrating the potential application of Bismuth-213 as a therapeutic for metastatic disease, bone marrow transplant, as well as treatments of fungal and bacterial infection.
Independent medical researchers welcomed the projected Actinium supply increases. "Clinical results to date have looked very promising, but lack of availability of the isotope Actinium-225 and the present high cost for that which is available has greatly limited the research," said Dr. Barbara Y. Croft, of the National Cancer Institute. "I am greatly encouraged that Isonics is working with IPPE to expand availability of Actinium-225, which will enable a greater number of promising research projects to proceed."
In clinical trials, Bismuth-213 has been used in a mode of cancer treatment called alpha immunotherapy, which researchers believe could lead to development of a so-called "magic bullet" for cancer treatment. The therapy involves the combination of alpha particle-emitting radio-nuclides -- in this case, Bismuth-213 -- with monoclonal antibodies or peptides that occur naturally in the human body. In the NIH research, the Bismuth-213 is combined with one such monoclonal antibody, and then injected into a cancer patient. The antibodies recognize and specifically bond to malignant cancer cells. When the Bismuth-213 decays, it imparts alpha particles into the cancerous cells with low risk of damaging the surrounding healthy cells.
BEST PICK 2005...double digit ate ao final do mes
-
Visitante
Quem está ligado:
Utilizadores a ver este Fórum: cmsbarros, Goya777, Kooc, latbal, m-m, malakas, Mr.Warrior, MR32, niceboy, Nuno V, nunorpsilva, OCTAMA, PAULOJOAO, paulopereira.pp36.pp, Phil2014, SerCyc, Shimazaki_2, yggy e 202 visitantes